Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

What symbol and exchange does Genelux shares trade?

Genelux trades on the NASDAQ stock market under the symbol GNLX.

What is Genelux stock price doing today?

As of October 30, 2026, GNLX stock price declined to $2.08 with 207,024 million shares trading.

What is Genelux's Beta?

GNLX has a beta of 1.90, meaning it tends to be more sensitive to market movements. GNLX has a correlation of 0.07 to the broad based SPY ETF.

How much is Genelux worth?

GNLX has a market cap of $94.11 million. This is considered a Micro Cap stock.

What is the highest and lowest price Genelux traded in the last 3 year period?

In the last 3 years, GNLX traded as high as $18.01 and as low as $1.60.

What are the top ETFs holding Genelux?

The top ETF exchange traded funds that GNLX belongs to (by Net Assets): VTI, VXF, IWC.

Is Genelux (GNLX) a good investment?

GNLX has underperformed the market in the last year with a price return of -73.9% while the SPY ETF gained +12.3%. GNLX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -31.8% and -14.0%, respectively, while the SPY returned +2.1% and -1.0%, respectively.

What are the support and resistance levels for Genelux (GNLX)?

GNLX support price is $1.98 and resistance is $2.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GNLX shares will trade within this expected range on the day.